ChristopherAndrewYasenchakMD

Oncology • Eugene, OR

Gastrointestinal Cancer, Hematologic Oncology

Willamette Valley Cancer Institute

Join to view full profile

Dr. Yasenchak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Yasenchak's full profile

Already have an account?

Office
520 Country Club Road
Eugene, OR 97401
Phone+1 541-683-5001

Fax+1 541-683-1422
Is this information wrong?

Summary

I am a board certified hematologist and medical oncologist with a special interest in clinical trials, phase I-III. My practice is largely centered around lymphoma, myeloma and gastrointestinal cancers.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003 - 2006
Johns Hopkins UniversityFellowship, Allergy and Immunology, 2002 - 2003
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Pennsylvania State University College of MedicineClass of 1999

Certifications & Licensure

OR State Medical License 2006 - 2025
WA State Medical License 2006 - 2015
MN State Medical License 2000 - 2010
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Portland Monthly Magazine Castle Connolly, 2011

Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma Start of enrollment: 2018 Nov 01
Terminated
Phase 1
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Active, not recruiting
Phase 1
Roles: Principal Investigator
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma Start of enrollment: 2023 Jun 22
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Dipti Patel-Donnelly, Timothy Larson, Ralph Boccia, Vivian J M Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Yasenchak, C. A., Jonathan W Friedberg, Rodolfo Bord...> ;Blood. 2024 Feb 29
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Pract...
Christopher Yasenchak, Nicholas Liu, April Beeks, Michelle Fanale, Nicholas Robert, Ding He, Kristina S Yu> ;JCO Oncology Practice. 2023 Oct 1
8 citations
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
18 citations
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Beth A. Hellerstedt, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Dana T. Aftab, David A. Ramies, Michael S. Gordon, Primo N. Lara> ;Clinical Lung Cancer. 2019 Mar 1
32 citations
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
David Andorsky, Kathryn S. Kolibaba, Sarit Assouline, Andres Forero-Torres, Vicky Jones, Leonard M. Klein, Dipti Patel-Donnelly, Mitchell R. Smith, Wei Ye, Wen Shi, Ch...> ;British Journal of Haematology. 2019 Jan 1
58 citations
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo Bordoni, Vivian Jean M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert T. Chen, Abraham P. Fon...> ;Blood. 2017 Dec 28
28 citations
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Sara M. Tolaney, Hovav Nechushtan, I. G. Ron, Patrick Schöffski, Ahmad Awada, Chris A. Yasenchak, A. Douglas Laird, Bridget O’Keeffe, Geoffrey I. Shapiro, Eric P. Winer> ;Breast Cancer Research and Treatment. 2016 Oct 6
95 citations
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome H. Goldschmidt, Robert T. Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Mari...> ;Blood. 2015 Dec 24
9 citations
Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.
Christopher A. Yasenchak, Wan-Yu Tseng, Mark Yap, Debra Rembert, Debra A. Patt> ;Leukemia & Lymphoma. 2015 Apr 10
146 citations
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Jeff P. Sharman, Michael J. Hawkins, Kathryn S. Kolibaba, Michael Boxer, Leonard M. Klein, Meihua Wu, Jing Hu, Steve Abella, Chris A. Yasenchak> ;Blood. 2015 Apr 9
25 citations
Response to Rituximab in Patients with Type II Cryoglobulinemia
Alan H. Bryce, Angela Dispenzieri, Robert A. Kyle, Martha Q. Lacy, S. Vincent Rajkumar, David J. Inwards, Christopher A. Yasenchak, Shaji Kumar, Morie A. Gertz> ;Clinical Lymphoma & Myeloma. 2006 Sep 1
Join now to see all

Journal Articles

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell Lymphoma
Jeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology

Abstracts/Posters

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Christopher A. Yasenchak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and ExpositionDecember 5th, 2019
Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCLDecember 22nd, 2015
More Treatment-Guiding Interim PET-CT Scans Needed in Advanced Stage Hodgkin LymphomaDecember 4th, 2023